Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 11;107(3):593–603. doi: 10.3324/haematol.2020.274456

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2022 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 2. — Kaplan-Meier plots for time to first treatment and overall survival based on genomic complexity stratification assessed by chromosome banding analysis and genomic microarrays. Kaplan-Meier estimation for time to first treatment (TTFT) (A) and overall survival (OS) (B) in patients classified in each category based on total number of aberrations found by chromosome banding analysis (CBA): non-complex karyotype (non-CK) (0-2 abnormalities [abn.]), low/intermediate-CK (3-4 abn.) or high-CK (≥5 abn.) (plots on the left) and based on total number of copy number aberrations (CNA) detected by genomic microarrays (GM): low-genomic complexity (GC) (0-2 CNA), intermediate-GC (3-4 CNA) or high-GC (≥5 CNA)] (plots on the right).